Check-Cap (NASDAQ:CHEK) Now Covered by StockNews.com

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report report published on Friday morning. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Stock Down 7.6 %

CHEK opened at $1.10 on Friday. The firm has a market cap of $6.44 million, a price-to-earnings ratio of -0.37 and a beta of 0.25. Check-Cap has a 52 week low of $0.56 and a 52 week high of $3.45. The business’s 50 day moving average is $0.96 and its two-hundred day moving average is $1.54.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.